Amiloride
Brand: Midamor (US/EU) / Amifru (IN) / Amilor (BD)
Antihypertensive
Potassium-sparing diuretic (Sodium channel blocker)
Pharmacokinetics
| Half-life | 6 hours |
| Tmax | 3 h |
| Bioavailability | 50 % (approx) |
| Protein Binding | 40 % |
| Volume of Distribution | 5 L/kg (approx) |
| Clearance Route | renal |
| Active Metabolites | no |
| Notes | Excreted unchanged in urine; duration of effect 24h; often combined with thiazides to minimize potassium loss; use caution in renal impairment. |
⚠️ Safety & Warnings
Severity: Moderate
Adverse Effects:
Hyperkalemia, nausea, vomiting, headache, fatigue
Contraindications:
Anuria, severe renal impairment, hyperkalemia
Precautions:
Monitor serum potassium and renal function; avoid potassium supplements or ACE inhibitors concurrently